UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):September 12, 2006
ST. JUDE MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Minnesota | 0-8672 | 41-1276891 |
---|
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
One Lillehei Plaza, St. Paul, MN | 55117 |
---|
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:(651) 483-2000
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On September 12, 2006 at the Bear Stearns 19th Annual Healthcare Conference in New York City, New York, St. Jude Medical, Inc. stated that it continues to expect third-quarter revenue for implantable cardioverter defibrillator heart devices to be in the $265 million to $295 million range provided at the time of its earnings release for the second quarter of this year.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ST. JUDE MEDICAL, INC. |
| | |
Date: September 13, 2006 | | By: | /s/ Pamela S. Krop
|
| | | Pamela S. Krop Vice President and General Counsel |